What's new

EMEA-002640-PIP01-19-M01

EMEA-002640-PIP01-19-M01

Feb 14, 2025 0

EMEA-002640-PIP01-19-M01

EMEA-002438-PIP02-19-M03

EMEA-002438-PIP02-19-M03

Feb 14, 2025 0

EMEA-002438-PIP02-19-M03

EMEA-002762-PIP02-20-M02

EMEA-002762-PIP02-20-M02

Feb 14, 2025 0

EMEA-002762-PIP02-20-M02

EMEA-002198-PIP01-21-M01

EMEA-002198-PIP01-21-M01

Feb 14, 2025 0

EMEA-002198-PIP01-21-M01

Opinion/decision on a Paediatric investigation plan (PIP): Agamree, Vamorolone, decision type: PM: decision on the application for modification of an agreed PIP, therapeutic area: Other, PIP number: P/0515/2023

Opinion/decision on a Paediatric investigation plan (PI...

Feb 14, 2025 0

Opinion/decision on a Paediatric investigation plan (PIP): Agamree, Vamorolone, ...

EMEA-002746-PIP01-20-M02

EMEA-002746-PIP01-20-M02

Feb 14, 2025 0

EMEA-002746-PIP01-20-M02

EMEA-002723-PIP01-19-M02

EMEA-002723-PIP01-19-M02

Feb 14, 2025 0

EMEA-002723-PIP01-19-M02

Opinion/decision on a Paediatric investigation plan (PIP): Olumiant, Baricitinib, decision type: PM: decision on the application for modification of an agreed PIP, therapeutic area: Immune system disorders, PIP number: P/0520/2023

Opinion/decision on a Paediatric investigation plan (PI...

Feb 14, 2025 0

Opinion/decision on a Paediatric investigation plan (PIP): Olumiant, Baricitinib...

Opinion/decision on a Paediatric investigation plan (PIP): Mounjaro, Tirzepatide, decision type: PM: decision on the application for modification of an agreed PIP, therapeutic area: Other, PIP number: P/0478/2023

Opinion/decision on a Paediatric investigation plan (PI...

Feb 14, 2025 0

Opinion/decision on a Paediatric investigation plan (PIP): Mounjaro, Tirzepatide...

PSUSA/00000789/202406

PSUSA/00000789/202406

Feb 14, 2025 0

PSUSA/00000789/202406

EMEA-001716-PIP04-19-M01

EMEA-001716-PIP04-19-M01

Feb 14, 2025 0

EMEA-001716-PIP04-19-M01

EMEA-001625-PIP01-14-M07

EMEA-001625-PIP01-14-M07

Feb 14, 2025 0

EMEA-001625-PIP01-14-M07

EMEA-001619-PIP03-16-M02

EMEA-001619-PIP03-16-M02

Feb 14, 2025 0

EMEA-001619-PIP03-16-M02

PSUSA/00002163/202407

PSUSA/00002163/202407

Feb 14, 2025 0

PSUSA/00002163/202407

EMEA-001716-PIP07-22

EMEA-001716-PIP07-22

Feb 14, 2025 0

EMEA-001716-PIP07-22

PSUSA/00000989/202406

PSUSA/00000989/202406

Feb 14, 2025 0

PSUSA/00000989/202406

EMEA-003467-PIP01-23

EMEA-003467-PIP01-23

Feb 14, 2025 0

EMEA-003467-PIP01-23

Human medicines European public assessment report (EPAR): Paxlovid, nirmatrelvir,ritonavir, Date of authorisation: 28/01/2022, Revision: 25, Status: Authorised

Human medicines European public assessment report (EPAR...

Feb 14, 2025 0

Human medicines European public assessment report (EPAR): Paxlovid, nirmatrelvir...

Opinion/decision on a Paediatric investigation plan (PIP): Enerzair Breezhaler, Indacaterol (acetate),Mometasone (furoate) (QVM149),Glycopyrronium bromide, decision type: PM: decision on the application for modification of an agreed PIP, therapeutic area: Pneumology-allergology, PIP number: P/0493/2023

Opinion/decision on a Paediatric investigation plan (PI...

Feb 14, 2025 0

Opinion/decision on a Paediatric investigation plan (PIP): Enerzair Breezhaler, ...

Human medicines European public assessment report (EPAR): Zinforo, ceftaroline fosamil, Date of authorisation: 22/08/2012, Revision: 28, Status: Authorised

Human medicines European public assessment report (EPAR...

Feb 14, 2025 0

Human medicines European public assessment report (EPAR): Zinforo, ceftaroline f...

Human medicines European public assessment report (EPAR): Karvea, irbesartan, Date of authorisation: 26/08/1997, Revision: 48, Status: Authorised

Human medicines European public assessment report (EPAR...

Feb 14, 2025 0

Human medicines European public assessment report (EPAR): Karvea, irbesartan, Da...

EMEA-001318-PIP01-12-M05

EMEA-001318-PIP01-12-M05

Feb 14, 2025 0

EMEA-001318-PIP01-12-M05

Opinion/decision on a Paediatric investigation plan (PIP): Skyrizi, Risankizumab, decision type: PM: decision on the application for modification of an agreed PIP, therapeutic area: Immunology-Rheumatology-Transplantation, PIP number: P/0492/2023

Opinion/decision on a Paediatric investigation plan (PI...

Feb 14, 2025 0

Opinion/decision on a Paediatric investigation plan (PIP): Skyrizi, Risankizumab...

Human medicines European public assessment report (EPAR): Beyfortus, nirsevimab, Date of authorisation: 31/10/2022, Revision: 11, Status: Authorised

Human medicines European public assessment report (EPAR...

Feb 14, 2025 0

Human medicines European public assessment report (EPAR): Beyfortus, nirsevimab,...

48
49
50
51
52

This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies.